Fast – Lean – Strategic

The healthcare industry is extremely complex

due to

  • regulatory issues
  • direct-to-patient marketing and
  • the powerful bond of privacy and trust between providers and patients.
Whether addressing physician or patient, we comprehend the fast changing issues involved in bettering the lives of patients.
The upside to better patient care is unlimited.

Your know – we know

AMG, AMNOG, ATC, Benefit Assessment of Pharmaceuticals, BfArM, Biologics, Biosimilars, BLA, BMG, Breakthrough Therapy Designation, CHMP, CME, Compassionate Use, Compliance, DocCheck, EC, EMA, EPAR, FDA, G-BA, Generic, HCP, HWG, ICD-10, INN, IQWiG, Labelling, Lay Audience, Leaflet, MAA, MHRA, NCI, NDA, NICE, NIH, NPP (§ 73,3 AMG), NUB, OD, Off-Label-Use, Orphan Drugs, OL, OTC, PBM, PDUFA, PEI, Pharmacovigilance, Positive Opinion, Priority Review Designation, RA, Recombinant, Reference Prices, SGB V, Small Molecule …

Our Clients:

Portola et al.

From now on AMGEN´s German HCP site uses Artificial intelligence (AI) for its digital assistant


Hematology & Oncology News


Treatment of Hemophilia

A new star in satisfying unmet medical needs recently launched

Gilead Sciences: Campus Infektiologie 2020

AMGEN Corporate Website Germany:

Joachim Freischem & Georg Puluj - Prinzenstr. 12 - D-80639 München (Nymphenburg)
Phone: +49/89/2020 9080 - VAT-No.: DE169293019 - - Datenschutzerklärung